Status:
COMPLETED
Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm
Lead Sponsor:
Medy-Tox
Conditions:
Essential Blepharospasm
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Meditoxin® in the treatment of Essential blepharospasm.
Eligibility Criteria
Inclusion
- Men and women aged above 18
- Subjects who was diagnosed with Essential Blepharospasm
- Subjects who voluntarily Signed written informed consent
- Subjects who can adhere to protocol and study requirements
Exclusion
- Subjects with known history of allergy considered due to Botulinum toxin type A
- Subjects who have received botulinum toxin A type within 3 months
- Any disease that might affect neuromuscular function (e.g.. Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis ect.)
- Subjects who are participating in other clinical trials
- Pregnant or lactating female Subjects
- Subjects who are not eligible for the study at the discretion of the Investigator.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT01259557
Start Date
August 1 2010
End Date
August 1 2011
Last Update
April 25 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Sevrance Hospital
Seoul, South Korea, 120-752
2
Seoul St.Mary Hospital
Seoul, South Korea, 137-040
3
Chung-Ang Univesity Yongsan Hospital
Seoul, South Korea, 140-883